Marty Makary Resigns as FDA Commissioner Amid Policy Disputes

2026-05-13

The BareStory

Dr. Marty Makary resigned as commissioner of the Food and Drug Administration on Tuesday after serving for more than a year. The president announced the resignation on social media and appointed Kyle Diamantas, a deputy commissioner for food policy, to serve as acting commissioner. The president also publicly shared a text message from Makary highlighting his work on drug approval processes.

Makary’s departure followed reported disagreements between the commissioner and the administration. According to a senior administration official and sources familiar with the matter, tensions involved the slow implementation of policies, including the approval of flavored e-cigarettes. Furthermore, anti-abortion organizations had recently demanded Makary’s removal, accusing him of delaying a safety review of the abortion medication mifepristone that was requested by Health and Human Services Secretary Robert F. Kennedy Jr.

The resignation concludes a tenure marked by internal agency challenges. Senior FDA officials accused Makary of micromanagement, a lack of transparency, and mishandling a fast-track drug voucher program. The agency has recently experienced leadership turmoil, including the departure of several career scientists and reports of declining staff morale.

Makary, a surgeon who had previously criticized the government’s response to the COVID-19 pandemic, was confirmed to lead the FDA in March 2025. Following his departure, a scheduled Senate subcommittee hearing was postponed. As acting commissioner, Diamantas will inherit the ongoing mifepristone review and upcoming regulatory negotiations with the pharmaceutical industry.

Left Perspective

Shielding Reproductive Civil Liberties
Defending Independent Scientific Accountability
Blocking Corporate Safety Shortcuts

Right Perspective

Enforcing Executive Policy Mandates
Prioritizing Traditional Social Order
Restoring Institutional Management Discipline

Left Perspective

• Shielding Reproductive Civil Liberties Valuing social progress and bodily autonomy, this camp views the pressure to accelerate the mifepristone safety review as a direct assault on established civil liberties. Makary’s ouster, driven explicitly by anti-abortion organizations and HHS Secretary Kennedy, signals an alarming politicization of medical oversight. They interpret the administration's willingness to purge a commissioner over delayed abortion medication reviews as a dangerous weaponization of federal agencies against vulnerable populations seeking care.

• Defending Independent Scientific Accountability Prioritizing transparent governance over political expediency, this perspective sees the mass departure of career FDA scientists as a critical institutional failure. Makary’s documented micromanagement and lack of transparency highlight the risks of appointing partisan critics to lead highly technical public health agencies. The resulting collapse in staff morale is viewed not merely as a workplace dispute, but as a systematic dismantling of the independent scientific expertise required to protect the public.

• Blocking Corporate Safety Shortcuts Focusing on consumer protection, this camp interprets the administration's frustration over delayed flavored e-cigarette approvals as prioritizing industry demands over public health. The mishandling of the fast-track drug voucher program further validates fears that vital regulatory guardrails are being actively dismantled. They warn that replacing Makary to push through accelerated approvals and lead pharmaceutical negotiations risks unleashing untested, potentially harmful products onto the market with minimal accountability.

Right Perspective

• Enforcing Executive Policy Mandates Valuing the rule of law and institutional hierarchy, this camp views administrative agencies as strictly subordinate to the elected executive branch. Makary’s failure to rapidly implement the administration’s core policies, including the delayed approval framework for e-cigarettes, represents unacceptable bureaucratic friction. His resignation is seen as a necessary enforcement of executive authority, ensuring that the FDA aligns with the authorized regulatory roadmap rather than operating as a rogue, slow-moving entity.

• Prioritizing Traditional Social Order Anchored in traditionalist values, this perspective views the stringent oversight of abortion medications as a fundamental moral and civic duty. The delay in completing the mifepristone safety review requested by HHS Secretary Kennedy is interpreted as an institutional failure to protect social order and uphold rigorous standards. By yielding to the demands of conservative advocacy groups, the administration successfully reaffirms its commitment to traditionalist principles and the strict scrutiny of morally contentious medical procedures.

• Restoring Institutional Management Discipline Prioritizing institutional continuity and operational stability, this side identifies Makary’s tenure as deeply disruptive to the FDA's core functioning. The allegations of micromanagement, lack of transparency, and the mishandling of fast-track voucher programs indicate a severe deficit in administrative competence. Appointing Kyle Diamantas as acting head is viewed as a pragmatic move to restore necessary operational discipline and steady leadership just as the agency enters critical negotiations with the pharmaceutical industry.

How it may affect me

As a U.S. reader:

• Short-term access to the abortion medication mifepristone may be affected as the new acting commissioner takes over an ongoing safety review prioritized by the administration.

• Consumers might soon see faster regulatory decisions or market availability for flavored e-cigarettes, as the agency aims to eliminate previous implementation delays.

• The speed and safety of new medications entering the market could change over the long term, depending on how new leadership manages the fast-track drug voucher program and upcoming negotiations with the pharmaceutical industry.

• The recent departure of career FDA scientists and internal morale issues could lead to long-term shifts in how rigorously the agency conducts independent safety reviews for food and drugs.

Marty Makary Resigns as FDA Commissioner Amid Policy Disputes

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at